Molecular regulation of ovarian cancer cell invasion

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11359-11366

  Sun, Ningxia ^a   Zhang, Qing ^a   Xu, Chen ^a   Zhao, Qian ^a   Ma, Yan ^a   Lu, Xinmei ^a   Wang, Liang ^a   Li, Wen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

MiR200; MMP3; Ovarian cancer; SMAD3; ZEB1

Indexed keywords

HOMEODOMAIN PROTEIN; MESSENGER RNA; MICRORNA; MIRN200 MICRORNA, HUMAN; MMP3 PROTEIN, HUMAN; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN; STROMELYSIN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

CELL MOTION; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 3; MICRORNAS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84927796903     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2434-7     Document Type: Article

References (24)

1. Dutta DK, Dutta I. Origin of ovarian cancer: molecular profiling. J Obstet Gynaecol India. 2013;63:152–7.
2. Di Leva G, Croce CM. MiRNA profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.
3. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.
4. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014;344:166–73.
5. Shah AA, Leidinger P, Blin N, Meese E. MiRNA: small molecules as potential novel biomarkers in cancer. Curr Med Chem. 2010;17:4427–32.
6. Jankovic R, Radulovic S, Brankovic-Magic M. SiRNA and miRNA for the treatment of cancer. J Buon. 2009;14 Suppl 1:S43–9.
7. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011;18:85–95.
8. Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol. 2010;116:117–25.
9. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009;114:457–64.
10. Jabbari N, Reavis AN, McDonald JF. Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells. J Ovarian Res. 2014;7:12.
11. Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD, Rice GE. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med. 2014;12:4.
12. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001;7:2396–404.
13. Smolarz B, Szyllo K, Romanowicz-Makowska H, Niewiadomski M, Kozlowska E, Kulig A. PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol. 2003;54:233–8.
14. Szyllo K, Smolarz B, Romanowicz-Makowska H, Niewiadomski M, Kozlowska E, Kulig A. The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer. J Exp Clin Cancer Res. 2002;21:357–61.
15. Cheng JC, Auersperg N, Leung PC. TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells. PLoS One. 2012;7:e42436.
16. Ahn SM, Cha JY, Kim J, Kim D, Trang HT, Kim YM, et al. Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene. 2012;31:3051–9.
17. Nakahata S, Yamazaki S, Nakauchi H, Morishita K. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene. 2010;29:4157–69.
18. Postigo AA. Opposing functions of ZEB proteins in the regulation of the TGFbeta/BMP signaling pathway. EMBO J. 2003;22:2443–52.
19. Xiao X, Wiersch J, El-Gohary Y, Guo P, Prasadan K, Paredes J, et al. TGFbeta receptor signaling is essential for inflammation-induced but not beta-cell workload-induced beta-cell proliferation. Diabetes. 2013;62:1217–26.
20. Massague J. TGFbeta in cancer. Cell. 2008;134:215–30.
21. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009;19:89–102.
22. Lan HY, Chung AC. Transforming growth factor-beta and Smads. Contrib Nephrol. 2011;170:75–82.
23. Tonge DP, Tugwood JD, Kelsall J, Gant TW. The role of microRNAs in the pathogenesis of MMPi-induced skin fibrodysplasia. BMC Genomics. 2013;14:338.
24. Soubani O, Ali AS, Logna F, Ali S, Philip PA, Sarkar FH. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis. 2012;33:1563–71.